agilon health Appoints Tim O'Rourke as CEO, Sets Ambitious Stock Price Targets for Equity Awards
Summary
agilon health has appointed Tim O'Rourke as its new Chief Executive Officer and President, effective May 7, 2026, with a compensation package that includes significant performance-based equity tied to ambitious stock price targets.
Key Events
-
New CEO Appointed
Tim O'Rourke has been appointed Chief Executive Officer and President, effective May 7, 2026. He will also join the Board of Directors as a Class III director.
-
Extensive Healthcare Industry Experience
Mr. O'Rourke brings over 25 years of leadership experience from companies like Help at Home, Centene Corporation, Ascension Complete LLC, and Humana, Inc., with deep expertise in Medicare Advantage and value-based care.
-
Performance-Based Equity Incentives
His compensation includes 200,000 performance-vesting restricted stock units (PSUs) that vest in tranches if the company's stock price reaches $50, $100, and $150 over a three-year period.
-
Leadership Continuity
Ronald A. Williams, who previously served as Executive Chairman, will continue in his role as Chairman of the Board, providing ongoing guidance.
Analysis
The appointment of Tim O'Rourke as the new Chief Executive Officer and President is a critical development for agilon health, especially following a period of significant operational and financial transformation and a recent reverse stock split. Mr. O'Rourke brings extensive experience in the healthcare industry, particularly in Medicare Advantage and value-based care, which aligns directly with the company's mission. His compensation package, including a substantial grant of 200,000 performance-vesting restricted stock units (PSUs) tied to ambitious stock price targets of $50, $100, and $150, strongly incentivizes him to drive significant shareholder value. This leadership change, coupled with the continuity of Ronald A. Williams as Chairman, signals a renewed strategic focus and a commitment to addressing the company's challenges, including its previous delisting threat.
At the time of this filing, AGL was trading at $25.40 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $420.5M. The 52-week trading range was $7.48 to $119.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.